Stiris Research Inc. Announces First Patients Dosed in Zucara’s Phase 1b Hypoglycemic Clamp Trial

London, Ontario — July 28, 2021 —

Stiris Research Inc. (“Stiris”), an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announced that the first patients have been dosed in a Phase 1b pharmacodynamic evaluation study of ZT-01 in Type 1 Diabetics (T1D) for sponsor Zucara Therapeutics Inc (“Zucara”).

Stiris is honoured to be working with Zucara on their clinical trial program for ZT-01.  This study will enroll approximately 25 T1D patients and will include hypoglycemic clamp procedures to define the safety and tolerability of this investigational product, as well as assess ZT-01’s effect on glucagon in this population.

“A once-daily therapy to prevent insulin-induced hypoglycemia could change the lives of many people with T1D. We are excited to help improve health outcomes in patients with diabetes and look forward to the study results,” said Urszula Bartlomiejska, Project Manager, Stiris Research, Inc.

Stiris and Zucara recently completed a single and multiple ascending dose Phase 1 trial, in which ZT-01 was safe and well-tolerated.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.